David John Simpson
Chief Executive Officer at Iksuda Therapeutics Ltd.
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Simon James Yvon Saxby | M | 65 |
Leaf Systems International Ltd.
 Leaf Systems International Ltd. Pharmaceuticals: OtherHealth Technology Leaf Systems International Ltd. is a contract research and British product development company that specializes in cutting-edge plant-based expression and production of proteins. The company is based in Norwich, UK. The company has a strong focus on research and development, utilizing their versatile technology and knowledge of plant biotechnology. The CEO of the company is Simon James Yvon Saxby. | - |
| William John Edward Burt | M | 56 |
Leaf Systems International Ltd.
Leaf Systems International Ltd. Pharmaceuticals: OtherHealth Technology Leaf Systems International Ltd. is a contract research and British product development company that specializes in cutting-edge plant-based expression and production of proteins. The company is based in Norwich, UK. The company has a strong focus on research and development, utilizing their versatile technology and knowledge of plant biotechnology. The CEO of the company is Simon James Yvon Saxby. | - |
| Georgina Anne Pope | M | 49 |
Leaf Systems International Ltd.
Leaf Systems International Ltd. Pharmaceuticals: OtherHealth Technology Leaf Systems International Ltd. is a contract research and British product development company that specializes in cutting-edge plant-based expression and production of proteins. The company is based in Norwich, UK. The company has a strong focus on research and development, utilizing their versatile technology and knowledge of plant biotechnology. The CEO of the company is Simon James Yvon Saxby. | - |
| Colin Malcolm Miles | M | - |
Leaf Systems International Ltd.
Leaf Systems International Ltd. Pharmaceuticals: OtherHealth Technology Leaf Systems International Ltd. is a contract research and British product development company that specializes in cutting-edge plant-based expression and production of proteins. The company is based in Norwich, UK. The company has a strong focus on research and development, utilizing their versatile technology and knowledge of plant biotechnology. The CEO of the company is Simon James Yvon Saxby. | - |
| Simon Eric Aspland | M | - |
Leaf Systems International Ltd.
Leaf Systems International Ltd. Pharmaceuticals: OtherHealth Technology Leaf Systems International Ltd. is a contract research and British product development company that specializes in cutting-edge plant-based expression and production of proteins. The company is based in Norwich, UK. The company has a strong focus on research and development, utilizing their versatile technology and knowledge of plant biotechnology. The CEO of the company is Simon James Yvon Saxby. | - |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Anthony David Baxter | M | 63 |
Iksuda Therapeutics Ltd.
 Iksuda Therapeutics Ltd. BiotechnologyHealth Technology Iksuda Therapeutics Ltd. operates as a biotechnology company which specializes in the development of next generation biotherapeutics. It creates new generation biological therapeutics through advanced glycosylation and conjugation technologies. The company has core expertise in protein/peptide fictionalization and glycosylation technologies, imparting improved pharmacokinetic properties to a broader range of biological therapeutics. It was founded by David John Simpson and Andrew Watts on November 21, 2007 and is headquartered in Newcastle upon Tyne, the United Kingdom. | - |
| Alan Peter Mackenzie Lamb | M | 74 |
Iksuda Therapeutics Ltd.
Iksuda Therapeutics Ltd. BiotechnologyHealth Technology Iksuda Therapeutics Ltd. operates as a biotechnology company which specializes in the development of next generation biotherapeutics. It creates new generation biological therapeutics through advanced glycosylation and conjugation technologies. The company has core expertise in protein/peptide fictionalization and glycosylation technologies, imparting improved pharmacokinetic properties to a broader range of biological therapeutics. It was founded by David John Simpson and Andrew Watts on November 21, 2007 and is headquartered in Newcastle upon Tyne, the United Kingdom. | 7 years |
| Bill Blair | M | 69 |
Iksuda Therapeutics Ltd.
Iksuda Therapeutics Ltd. BiotechnologyHealth Technology Iksuda Therapeutics Ltd. operates as a biotechnology company which specializes in the development of next generation biotherapeutics. It creates new generation biological therapeutics through advanced glycosylation and conjugation technologies. The company has core expertise in protein/peptide fictionalization and glycosylation technologies, imparting improved pharmacokinetic properties to a broader range of biological therapeutics. It was founded by David John Simpson and Andrew Watts on November 21, 2007 and is headquartered in Newcastle upon Tyne, the United Kingdom. | 1 years |
| Samuel Cameron Williams | M | 55 |
Iksuda Therapeutics Ltd.
Iksuda Therapeutics Ltd. BiotechnologyHealth Technology Iksuda Therapeutics Ltd. operates as a biotechnology company which specializes in the development of next generation biotherapeutics. It creates new generation biological therapeutics through advanced glycosylation and conjugation technologies. The company has core expertise in protein/peptide fictionalization and glycosylation technologies, imparting improved pharmacokinetic properties to a broader range of biological therapeutics. It was founded by David John Simpson and Andrew Watts on November 21, 2007 and is headquartered in Newcastle upon Tyne, the United Kingdom. | - |
| Michael Owen | M | 73 |
Iksuda Therapeutics Ltd.
Iksuda Therapeutics Ltd. BiotechnologyHealth Technology Iksuda Therapeutics Ltd. operates as a biotechnology company which specializes in the development of next generation biotherapeutics. It creates new generation biological therapeutics through advanced glycosylation and conjugation technologies. The company has core expertise in protein/peptide fictionalization and glycosylation technologies, imparting improved pharmacokinetic properties to a broader range of biological therapeutics. It was founded by David John Simpson and Andrew Watts on November 21, 2007 and is headquartered in Newcastle upon Tyne, the United Kingdom. | - |
| Andrew Watts | M | - |
Iksuda Therapeutics Ltd.
Iksuda Therapeutics Ltd. BiotechnologyHealth Technology Iksuda Therapeutics Ltd. operates as a biotechnology company which specializes in the development of next generation biotherapeutics. It creates new generation biological therapeutics through advanced glycosylation and conjugation technologies. The company has core expertise in protein/peptide fictionalization and glycosylation technologies, imparting improved pharmacokinetic properties to a broader range of biological therapeutics. It was founded by David John Simpson and Andrew Watts on November 21, 2007 and is headquartered in Newcastle upon Tyne, the United Kingdom. | - |
| Cassie Doherty | M | - |
Iksuda Therapeutics Ltd.
Iksuda Therapeutics Ltd. BiotechnologyHealth Technology Iksuda Therapeutics Ltd. operates as a biotechnology company which specializes in the development of next generation biotherapeutics. It creates new generation biological therapeutics through advanced glycosylation and conjugation technologies. The company has core expertise in protein/peptide fictionalization and glycosylation technologies, imparting improved pharmacokinetic properties to a broader range of biological therapeutics. It was founded by David John Simpson and Andrew Watts on November 21, 2007 and is headquartered in Newcastle upon Tyne, the United Kingdom. | - |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United Kingdom | 12 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- David John Simpson
- Personal Network
